On September 8, 2018, the French pharmaceutical company Ipsen announced that it would build an anti-cancer drugs manufacturing plant in Algeria in collaboration with a local group, Isly Holding.

The plant, a 300-m² construction located in the technological pole at Sidi Abdellah will require a €20 million investment.

“The land parcel plan for the future oncology medicine manufacturing plant has been validated by competent bodies. With this, we will lay its cornerstone by the end of this year”, Adlane Soudani, Ipsen Pharma Algérie’s CEO indicated during a press conference held by Ipsen and Isly Holding’s management.

The production plant should be commissioned in 2021. “The priority is to have an operational plant, able to manufacture approved drugs, built within deadlines”, Benoit Hennion, Ipsen’s executive vice president said.  

The plant’s production will initially be sold on the local market and later exported.